Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
thyroid eye disease (ted)medical
An inflammatory condition in which the immune system attacks the tissues and muscles around the eyes, causing swelling, bulging, double vision, pain and, in severe cases, loss of sight. It matters to investors because its severity and prevalence drive demand for drugs, surgeries and diagnostics, influence healthcare spending and regulatory decisions, and can meaningfully affect revenue and valuations for companies developing or selling treatments—like a busted pipe creating urgent repair needs.
A cell-surface protein that acts like an antenna for the growth hormone called insulin-like growth factor 1 (IGF-1); when IGF-1 binds, the receptor sends signals that drive cell growth, survival and division. It matters to investors because drugs that block or modify this receptor are pursued for cancer and metabolic diseases, so clinical trial results, safety findings or regulatory decisions involving IGF-1R can sharply affect the value of companies developing such treatments.
Thyroid-stimulating hormone receptor (TSHR) is a protein on thyroid cells that acts like a lock for the hormone TSH, turning on thyroid hormone production when the hormone binds—think of TSH as a key and TSHR as the lock. It matters to investors because drugs, tests, or diagnostics that target this receptor can change how thyroid diseases are treated, diagnosed, or monitored, affecting potential market size and company value. Changes in this receptor’s activity are central to common thyroid disorders and related therapies.
neonatal fc receptor (fcrn) inhibitorsmedical
Neonatal Fc receptor (FcRn) inhibitors are drugs that block a protein responsible for recycling IgG antibodies, causing those antibodies to be cleared from the bloodstream faster. Think of FcRn as a recycling center for antibodies; inhibitors shut the center down so harmful antibodies that drive autoimmune diseases are reduced. For investors, these drugs matter because they address a broad range of immune-driven conditions, influence clinical trial and regulatory risk, and can affect market opportunity, pricing and long-term revenue potential.
autoinjectortechnical
A prefilled, spring‑loaded medical device that automatically delivers a measured dose of medication beneath the skin when pressed against the body, like a self‑operating syringe packaged for quick use. Investors care because autoinjectors can increase patient safety, adherence and convenience — factors that drive demand, shape reimbursement and regulatory review, and affect a product’s market size, manufacturing complexity and competitive moat.
pivotal programmedical
A pivotal program is the set of late-stage clinical trials and supporting studies designed to prove a drug or medical device is safe and effective enough for regulatory approval. Investors care because successful pivotal results are like passing a final exam that unlocks market access and revenue, while failures can halt a product and sharply reduce a company’s value.
webcasttechnical
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
WALTHAM, Mass.--(BUSINESS WIRE)--
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY
Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL
A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay will be available following each event.
About Viridian Therapeutics
Viridian is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with autoimmune and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases.
Viridian is advancing multiple late-stage, anti-insulin-like growth factor-1 receptor (IGF-1R) candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company conducted a pivotal program for veligrotug, including two global phase 3 clinical trials, THRIVE and THRIVE-2, to evaluate its efficacy and safety in patients with active and chronic TED. THRIVE and THRIVE-2 reported positive topline data, meeting their primary endpoints and all secondary endpoints. Viridian is also advancing elegrobart as the potential first subcutaneous autoinjector for the treatment of TED. Viridian is conducting an ongoing pivotal program for elegrobart, including two global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of elegrobart in patients with active and chronic TED. REVEAL-1 and REVEAL-2 reported positive topline data, meeting their primary endpoints and multiple secondary endpoints.
In addition to its IGF‑1R inhibitor portfolio, Viridian is developing an anti–thyroid‑stimulating hormone receptor (TSHR) program designed as a potential therapy for TED and Graves’ disease.
Viridian is also advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which have the potential to be developed in multiple autoimmune diseases.
